From Bench to Fireside

In this episode, physician-scientist Christopher A. Klebanoff, MD, a PICI Network Investigator at Memorial Sloan Kettering Cancer Center, provides an inside look at his groundbreaking research on optimizing T-cell activation for cancer immunotherapy. Dr. Klebanoff discusses his work on targeting mutated driver oncogenes, expanding cell therapies beyond blood cancers, and using CD4+ T cells to improve cancer outcomes. Tracing the evolution of the field from pioneers like Dr. William Coley to current leaders such as Nobel laureate Jim Allison, PhD, Center Director for the PICI Center at MD Anderson, Dr. Klebanoff explains why multidisciplinary collaboration is essential to driving progress in cancer immunotherapy.

Get ready to go from bench to fireside with Dr. Klebanoff.

++

From Bench to Fireside™ is a new podcast from the Parker Institute for Cancer Immunotherapy (PICI) that takes you from behind the lab bench to the frontiers of cancer research. Each episode features an interview with members of the PICI Network, pioneers in cancer immunotherapy and leaders at world-renowned cancer research institutions. Throughout the conversations, these experts weigh in on the potential of the human immune system to target and eradicate cancer cells, from the latest breakthroughs in immuno-oncology to their impact on patients. Along the way, they unpack the hurdles encountered and the opportunities that lie ahead.

Tune in to hear from scientific leaders who stand at the forefront of developing breakthrough immune therapies with the goal of turning all cancers into curable diseases.

From Bench to Fireside™ is produced by the Parker Institute for Cancer Immunotherapy. Follow PICI on LinkedIn, X @parkerici or visit https://www.parkerici.org/.